SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

The revenue for the December 2022 quarter is pegged at Rs. 46457.50 millions, about 23.21% up against Rs. 37706.60 millions recorded during the year-ago period.A slender decline of -5.57% was recorded to Rs. 4867.30  millions from Rs. 5154.30 millions in the corresponding previous quarter.OP of the company witnessed a marginal growth to 10674.10 millions from 9616.20 millions in the same quarter last year.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202212 202112 % Var 202212 202112 % Var 202203 202103 % Var
Sales 46457.50 37706.60 23.21 148639.20 115791.00 28.37 155859.80 141160.50 10.41
Other Income 746.30 3132.50 -76.18 2925.50 8092.10 -63.85 11968.80 1920.70 523.15
PBIDT 10674.10 9616.20 11.00 42709.40 25651.90 66.50 38654.40 24490.80 57.83
Interest 1308.90 854.70 53.14 3107.30 2969.10 4.65 3881.00 2675.20 45.07
PBDT 9365.20 8761.50 6.89 39602.10 21027.10 88.34 16568.10 20920.00 -20.80
Depreciation 4304.40 3552.40 21.17 11888.90 9958.10 19.39 13499.50 12364.30 9.18
PBT 5060.80 5209.10 -2.85 27713.20 11069.00 150.37 3068.60 8555.70 -64.13
TAX 193.50 54.80 253.10 597.80 -793.20 -175.37 4068.50 131.70 2989.22
Deferred Tax 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
PAT 4867.30 5154.30 -5.57 27115.40 11862.20 128.59 -999.90 8424.00 -111.87
Equity 2399.30 2399.30 0.00 2399.30 2399.30 0.00 2399.30 2399.30 0.00
PBIDTM(%) 22.98 25.50 -9.91 28.73 22.15 29.70 24.80 17.35 42.95

Sun Pharma Inds. Share Price

1675.20 -17.95 (-1.06%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×